Loading...

Astellas Pharma gets FDA fast track status for ASP036 to treat primary mitochondrial myopathies

Print Friendly, PDF & Email

Astellas Pharma has secured fast track status from the US Food and Drug Administration (FDA) to develop ASP0367/MA-0211 (ASP0367) as a potential treatment for primary mitochondrial myopathies (PMM). The US FDA’s Center for Drug Evaluation and Research. (Credit: The U.S. Food and Drug Administration) PMM is a complex mitochondrial […]